These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 19941668)
1. Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities. Meghani SH; Lee CS; Hanlon AL; Bruner DW BMC Med Inform Decis Mak; 2009 Nov; 9():47. PubMed ID: 19941668 [TBL] [Abstract][Full Text] [Related]
2. Use of forecasted assessment of quality of life to validate time-trade-off utilities and a prostate cancer screening decision-analytic model. Cantor SB; Deshmukh AA; Krahn MD; Volk RJ Health Expect; 2015 Oct; 18(5):1610-20. PubMed ID: 26039695 [TBL] [Abstract][Full Text] [Related]
3. A (Latent) Class of Their Own: Response Patterns in Trading Off Quantity and Quality of Life in Time Trade-Off Exercises. van Nooten FE; Houghton K; van Exel J; van Agthoven M; Brouwer WBF; Stull DE Value Health; 2017 Dec; 20(10):1403-1410. PubMed ID: 29241900 [TBL] [Abstract][Full Text] [Related]
4. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. Bruner DW; Hanlon A; Mazzoni S; Raysor S; Konski A; Hanks G; Pollack A Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):34-42. PubMed ID: 14697418 [TBL] [Abstract][Full Text] [Related]
5. Utilities for prostate cancer health states in men aged 60 and older. Stewart ST; Lenert L; Bhatnagar V; Kaplan RM Med Care; 2005 Apr; 43(4):347-55. PubMed ID: 15778638 [TBL] [Abstract][Full Text] [Related]
6. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Saigal CS; Gornbein J; Reid K; Litwin MS Qual Life Res; 2002 Aug; 11(5):405-14. PubMed ID: 12113388 [TBL] [Abstract][Full Text] [Related]
7. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Krahn M; Ritvo P; Irvine J; Tomlinson G; Bremner KE; Bezjak A; Trachtenberg J; Naglie G Med Care; 2003 Jan; 41(1):153-64. PubMed ID: 12544552 [TBL] [Abstract][Full Text] [Related]
8. Predictors of utilities for health states in early stage prostate cancer. Saigal CS; Gornbein J; Nease R; Litwin MS J Urol; 2001 Sep; 166(3):942-6. PubMed ID: 11490251 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the Trade-Offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study. Watson V; McCartan N; Krucien N; Abu V; Ikenwilo D; Emberton M; Ahmed HU J Urol; 2020 Aug; 204(2):273-280. PubMed ID: 31967521 [TBL] [Abstract][Full Text] [Related]
10. How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. Mazur DJ; Merz JF J Am Geriatr Soc; 1996 Aug; 44(8):934-7. PubMed ID: 8708303 [TBL] [Abstract][Full Text] [Related]
11. Identification of Preference "Phenotypes" in Men With Prostate Cancer. Saigal C; Hollenbeck B; Penson D; Williams K; Kwan L; Saucedo J; Bergman J Urol Pract; 2024 Jul; 11(4):717-725. PubMed ID: 38899681 [TBL] [Abstract][Full Text] [Related]
12. Preferences for Prostate Cancer Outcomes: A Comparison of the Patient Perspective, the General Population Perspective, and a Population at Risk for Prostate Cancer. Gries KS; Regier DA; Ramsey SD; Patrick DL Value Health; 2016; 19(2):218-25. PubMed ID: 27021756 [TBL] [Abstract][Full Text] [Related]
13. A multi-attribute model of prostate cancer patient's preferences for health states. Chapman GB; Elstein AS; Kuzel TM; Nadler RB; Sharifi R; Bennett CL Qual Life Res; 1999 May; 8(3):171-80. PubMed ID: 10472149 [TBL] [Abstract][Full Text] [Related]
14. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688 [TBL] [Abstract][Full Text] [Related]
15. Investigating the Heterogeneity in Women's Preferences for Breast Screening: Does the Communication of Risk Matter? Vass CM; Rigby D; Payne K Value Health; 2018 Feb; 21(2):219-228. PubMed ID: 29477404 [TBL] [Abstract][Full Text] [Related]
16. Patient preferences for outcomes associated with surgical management of prostate cancer. Smith DS; Krygiel J; Nease RF; Sumner W; Catalona WJ J Urol; 2002 May; 167(5):2117-22. PubMed ID: 11956454 [TBL] [Abstract][Full Text] [Related]
17. Older patients' willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer. Mazur DJ; Merz JF J Am Geriatr Soc; 1995 Sep; 43(9):979-84. PubMed ID: 7657938 [TBL] [Abstract][Full Text] [Related]
18. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls? Korfage IJ; de Koning HJ; Habbema JD; Schröder FH; Essink-Bot ML BJU Int; 2007 Apr; 99(4):801-6. PubMed ID: 17233804 [TBL] [Abstract][Full Text] [Related]
19. Estimating preferences for treatments in patients with localized prostate cancer. Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M; Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504 [TBL] [Abstract][Full Text] [Related]
20. Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. König HH; Günther OH; Angermeyer MC; Roick C Pharmacoeconomics; 2009; 27(5):405-19. PubMed ID: 19586078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]